H89974 H8 Ruling Active

The tariff classification of Pemetrexed Disodium Heptahydrate (CAS-357166-29-1), imported in bulk form, and ALIMTA® (pemetrexed injection), from Ireland

Issued April 11, 2002 by U.S. Customs and Border Protection.

Tariff classification

HTS codes: 3004.90.9115, 2933.59.5300

Headings: 3004, 2933

Product description

The first product, Pemetrexed Disodium Heptahydrate, is an investigational drug currently being evaluated, in FDA Phase III clinical trials, for use in the treatment of malignant pleural mesothelioma. The second product, ALIMTA® (pemetrexed injection), is an injectable dosage form of Pemetrexed.

CBP rationale

The applicable subheading for Pemetrexed Disodium Heptahydrate, imported in bulk form, will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other. The applicable subheading for ALIMTA® (pemetrexed injection), put up in dosage form, will be 3004.90.9115, HTS, which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Antineoplastic and immunosuppressive medicaments.

Full text

NY H89974 April 11, 2002 CLA-2-29:RR:NC:2:238 H89974 CATEGORY: Classification TARIFF NO.: 2933.59.5300; 3004.90.9115 Mr. John C. O’Connor Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 RE: The tariff classification of Pemetrexed Disodium Heptahydrate (CAS-357166-29-1), imported in bulk form, and ALIMTA® (pemetrexed injection), from Ireland Dear Mr. O’Connor: In your letter dated March 19, 2002, you requested a tariff classification ruling. The first product, Pemetrexed Disodium Heptahydrate, is an investigational drug currently being evaluated, in FDA Phase III clinical trials, for use in the treatment of malignant pleural mesothelioma. The second product, ALIMTA® (pemetrexed injection), is an injectable dosage form of Pemetrexed. The applicable subheading for Pemetrexed Disodium Heptahydrate, imported in bulk form, will be 2933.59.5300, Harmonized Tariff Schedule of the United States (HTS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.” The rate of duty will be 6.5 percent ad valorem. For the record, we note that, while “Pemetrexed” is listed in Table 1 of the Pharmaceutical Appendix to the Tariff Schedule and the suffix “Disodium” is listed in Table 2 of the Pharmaceutical Appendix to the Tariff Schedule, the suffix “heptahydrate” is not listed in Table 2 of said appendix. Accordingly, pursuant to General Note 13, HTS, Pemetrexed Disodium Heptahydrate is not eligible for duty-free treatment at the present time. The applicable subheading for ALIMTA® (pemetrexed injection), put up in dosage form, will be 3004.90.9115, HTS, which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Antineoplastic and immunosuppressive medicaments.” The rate of duty will be free. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 301-443-1544. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

N334168 August 15, 2023

The tariff classification of Ensifentrine (CAS No. 1884461-72-6) in bulk powder form, from Portugal

N329297 December 7, 2022

The tariff classification of Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk powder form, from Taiwan

N329037 November 21, 2022

The tariff classification of Trilaciclib Dihydrochloride (CAS No. 1977495-97-8) and Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk form, from Taiwan

N320984 September 7, 2021

The tariff classification of Vibegron (CAS No. 1190389-15-1) in bulk form, from India

N318947 May 14, 2021

The tariff classification of Vericiguat (CAS No. 1350653-20-1) in bulk form and Verquvo® Tablets in dosage form, from Germany

N317830 March 22, 2021

The tariff classification of Sitagliptin Phosphate Monohydrate (CAS No. 654671-77-9) in bulk form, from Spain

N303158 March 15, 2019

The tariff classification of Bicalutamide (CAS No. 90357-06-5), Linagliptin (CAS No. 668270-12-0) and Aripiprazole (CAS No. 129722-12-9) in bulk powder form, from India

N303161 March 15, 2019

The tariff classification of Imatinib (CAS No. 152459-95-5) and Tofacitinib Citrate (CAS No. 540737-29-9) in bulk powder form, from Italy

N302078 December 20, 2018

The tariff classification of VITRAKVI™ capsules in dosage form and Larotrectinib (CAS No. 1223403-58-4) in bulk form, from the United States and imported from the United Kingdom

N298223 July 16, 2018

The tariff classification of Sitagliptin Phosphate Monohydrate (CAS No. 654671-77-9), Spironolactone (CAS No. 52-01-7) and Ticagrelor (CAS No. 274693-27-5) in bulk form, from India

Searching CBP rulings the smart way

TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.

Book a demo →